Breaking News

Optibrium Acquires BioPharmics

Acquisition adds technology for 3D ligand- and structure-based design into Optibrium's StarDrop platform for small molecule design, optimization, and analysis.

Optibrium, a developer of software and AI solutions for drug discovery, acquired BioPharmics LLC, a move that will expand its 3D drug design and modelling offering. BioPharmics’ CEO, Ajay Jain, and director of applied science, Ann Cleves, join Optibrium, respectively focusing on R&D and application science in the newly created BioPharmics Division. BioPharmics has developed a series of algorithms and software for 3D ligand-based and structure-based computational drug design, including sof...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters